MEP Instruments rebrands as Metrohm Australia, Metrohm New Zealand
In response to changes in the ownership structure of the company and the successful expansion of its business operation, MEP Instruments will change its name to Metrohm Australia and Metrohm New Zealand.
Effective 1 January 2018, the distributor of analytical technology solutions will be operating under the name of Metrohm, its parent company. The change will reflect the close integration of the Australian and New Zealand operation under the global Metrohm brand.
Metrohm is a global leader in the fields of titration and voltammetry and an innovator in ion chromatography, online analysis and laboratory automation, as well as NIR Raman spectroscopy and electrochemical solutions for research and training.
MEP Instruments Australia and New Zealand was established by Metrohm Switzerland together with Anton Paar Austria nearly 20 years ago to strengthen support and service for their customer base in these countries. The success over the past years and the enthusiastic acceptance by the scientific community in the region have led to the decision to change the name to Metrohm to reflect the commitment to the growing customer base in the region and to establish Anton Paar Australia and New Zealand as a separate entity.
“While our company name is changing, the core elements of the organisation will remain the same,” said Reto Broger, managing director of MEP. “Metrohm Australia and Metrohm New Zealand will continue to provide our customers with the most advanced analytical solutions from Metrohm and other leading manufacturers, such as Retsch and Retsch Technology.”
Along with the name change, the company will adopt the corporate identity, including the logo and visual identity, of parent company Metrohm. The changes will be effective 1 January 2018, from which date business activities will be undertaken with the new corporate name. All MEP/Metrohm office addresses and phone numbers will remain the same across Australia and New Zealand.
Originally published here.
Abcam has announced the asset purchase of the gene editing platform and oncology product...
Professor Lisa Kewley has been awarded the 2020 James Craig Watson Medal by the US National...
Caplacizumab is said to be the first nanobody therapy to treat adults with the rare autoimmune...